Monte Rosa Therapeutics Stock Performance
| GLUE Stock | USD 16.01 1.61 11.18% |
Monte Rosa holds a performance score of 16 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 0.72, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Monte Rosa's returns are expected to increase less than the market. However, during the bear market, the loss of holding Monte Rosa is expected to be smaller as well. Use Monte Rosa Therapeutics sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on Monte Rosa Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Monte Rosa Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Monte Rosa exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 11.18 | Five Day Return 1.84 | Year To Date Return 4.57 | Ten Year Return (24.41) | All Time Return (24.41) |
1 | Applying sector rotation models to Monte Rosa Therapeutics Inc. - Trade Ideas Verified Technical Trade Signals - newser.com | 10/10/2025 |
2 | Monte Rosa Therapeutics Reports Q3 Loss, Tops Revenue Estimates | 11/06/2025 |
3 | Los Angeles Capital Management LLC Makes New Investment in Monte Rosa Therapeutics, Inc. GLUE - MarketBeat | 11/20/2025 |
4 | Hillsdale Investment Management Inc. Makes New 271,000 Investment in Monte Rosa Therapeutics, Inc. GLUE - MarketBeat | 11/26/2025 |
5 | Improved Revenues Required Before Monte Rosa Therapeutics, Inc. Stocks 26 percent Jump Looks Justified - | 12/01/2025 |
6 | Monte Rosa Therapeutics Sets New 52-Week High - Heres Why - MarketBeat | 12/04/2025 |
7 | Disposition of 75011 shares by Sharon Townson of Monte Rosa at 1.13 subject to Rule 16b-3 | 12/05/2025 |
8 | Monte Rosa Therapeutics Nasdaq Futures Biotech Momentum | 12/09/2025 |
9 | Is MRT-2359 Prostate Cancer Data Update Altering The Investment Case For Monte Rosa Therapeutics | 12/16/2025 |
10 | Analysts Offer Insights on Healthcare Companies Novan and Monte Rosa Therapeutics - The Globe and Mail | 12/18/2025 |
11 | Monte Rosa Therapeutics Shares Down 6.4 percent - Heres Why - MarketBeat | 12/29/2025 |
12 | Acquisition by Sharon Townson of 35000 shares of Monte Rosa subject to Rule 16b-3 | 01/02/2026 |
13 | Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results | 01/06/2026 |
| Begin Period Cash Flow | 132.7 M | |
| Total Cashflows From Investing Activities | -44.5 M |
Monte Rosa Relative Risk vs. Return Landscape
If you would invest 846.00 in Monte Rosa Therapeutics on October 9, 2025 and sell it today you would earn a total of 755.00 from holding Monte Rosa Therapeutics or generate 89.24% return on investment over 90 days. Monte Rosa Therapeutics is currently generating 1.206% in daily expected returns and assumes 5.719% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Monte, and 76% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Monte Rosa Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Monte Rosa's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Monte Rosa Therapeutics, and traders can use it to determine the average amount a Monte Rosa's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2109
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GLUE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Monte Rosa is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Monte Rosa by adding it to a well-diversified portfolio.
Monte Rosa Fundamentals Growth
Monte Stock prices reflect investors' perceptions of the future prospects and financial health of Monte Rosa, and Monte Rosa fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Monte Stock performance.
| Return On Equity | 0.0928 | ||||
| Return On Asset | 0.0137 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | (2.58) % | ||||
| Current Valuation | 586.28 M | ||||
| Shares Outstanding | 65.12 M | ||||
| Price To Earning | 1.91 X | ||||
| Price To Book | 3.81 X | ||||
| Price To Sales | 5.74 X | ||||
| Revenue | 75.62 M | ||||
| Gross Profit | 50.97 M | ||||
| EBITDA | (72.99 M) | ||||
| Net Income | (72.7 M) | ||||
| Cash And Equivalents | 294.14 M | ||||
| Cash Per Share | 6.32 X | ||||
| Total Debt | 42.72 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 20.11 X | ||||
| Book Value Per Share | 3.98 X | ||||
| Cash Flow From Operations | 42 M | ||||
| Earnings Per Share | 0.32 X | ||||
| Market Capitalization | 1.04 B | ||||
| Total Asset | 438.73 M | ||||
| Retained Earnings | (438.59 M) | ||||
| Working Capital | 220.49 M | ||||
About Monte Rosa Performance
By analyzing Monte Rosa's fundamental ratios, stakeholders can gain valuable insights into Monte Rosa's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Monte Rosa has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Monte Rosa has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.38) | (0.36) |
Things to note about Monte Rosa Therapeutics performance evaluation
Checking the ongoing alerts about Monte Rosa for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Monte Rosa Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Monte Rosa is way too risky over 90 days horizon | |
| Monte Rosa appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 75.62 M. Net Loss for the year was (72.7 M) with profit before overhead, payroll, taxes, and interest of 50.97 M. | |
| Monte Rosa has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results |
- Analyzing Monte Rosa's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Monte Rosa's stock is overvalued or undervalued compared to its peers.
- Examining Monte Rosa's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Monte Rosa's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Monte Rosa's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Monte Rosa's stock. These opinions can provide insight into Monte Rosa's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Monte Stock analysis
When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |